Juan Zhu1, Le Wang1, Hui-Yao Huang1, Fang-Zhou Bai1, Jing Li2, Yi Fang3, Yong Wang4, A-Yan Mao5, Xian-Zhen Liao6, Guo-Xiang Liu7, Ya-Na Bai8, Jian-Song Ren1, Xiao-Jie Sun9, Lan-Wei Guo10, De-Bin Wang11, Heng-Jin Dong12, Jia-Lin Wang13, Xiao-Jing Xing14, Qi Zhou15, Lin Zhu16, Ling-Bin Du17, Bing-Bing Song18, Su-Xia Luo10, Yu-Qin Liu19, Ying Ren20, Jin-Yi Zhou21, Xiao-Hua Sun22, Li Lan23, Shou-Ling Wu24, Xiao Qi25, Pei-An Lou26, Fei Ma27, Ni Li1, Kai Zhang28, Wan-Qing Chen1, Jie He29, Min Dai1, Ju-Fang Shi1. 1. Office of Cancer Screening, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS&PUMC), Beijing, China. 2. Department of Diagnostic Radiology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, CAMS&PUMC, Beijing, China. 3. Department of Breast Surgical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, CAMS&PUMC, Beijing, China. 4. Department of Ultrasound, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, CAMS&PUMC, Beijing, China. 5. Public Health Information Research Office, Institute of Medical Information, CAMS&PUMC, Beijing, China. 6. Hunan Office for Cancer Control and Research, Hunan Cancer Hospital, Changsha, China. 7. Department of Health Economics, School of Health Management, Harbin Medical University, Harbin, China. 8. Institute of Epidemiology and Health Statistics, Lanzhou University, Lanzhou, China. 9. Center for Health Management and Policy, Key Lab of Health Economics and Policy, Shandong University, Jinan, China. 10. Department of Institute of Tumor Research, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China. 11. School of Health Service Management, Anhui Medical University, Hefei, China. 12. Center for Health Policy Studies, Zhejiang University School of Medicine, Hangzhou, China. 13. Science and Education Department of Public Health Division, Shandong Tumor Hospital, Jinan, China. 14. Liaoning Office for Cancer Control and Research, Liaoning Cancer Hospital and Institute, Shenyang, China. 15. Chongqing Office for Cancer Control and Research, Chongqing Cancer Institute, Chongqing, China. 16. Teaching and Research Department, Affiliated Cancer Hospital of Xinjiang Medical University, Urumqi, China. 17. Cancer Prevention and Control Office, Institute of Cancer Research and Basic Medical Sciences of Chinese Academy of Sciences/Cancer Hospital of University of Chinese Academy of Sciences/Zhejiang Cancer Hospital, Hangzhou, China. 18. Heilongjiang Office for Cancer Control and Research, Affiliated Cancer Hospital of Harbin Medical University, Harbin, China. 19. Cancer Epidemiology Research Center, Gansu Provincial Cancer Hospital, Lanzhou, China. 20. Urban Office of Cancer Early Detection and Treatment, Tieling Central Hospital, Tieling, China. 21. Institute of Chronic Non-communicable Diseases Prevention and Control, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China. 22. Ningbo Clinical Cancer Prevention Guidance Center, Ningbo No. 2 Hospital, Ningbo, China. 23. Institute of Chronic Disease Prevention and Control, Harbin Center for Disease Control and Prevention, Harbin, China. 24. Health Department of Kailuan Group, Kailuan General Hospital, Tangshan, China. 25. Department of Occupational Medicine, Tangshan People's Hospital, Tangshan, China. 26. Department of Control and Prevention of Chronic Non-communicable Diseases, Xuzhou Center for Disease Control and Prevention, Xuzhou, China. 27. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, CAMS&PUMC, Beijing, China. 28. Cancer Department of Physical Examination, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, CAMS&PUMC, Beijing, China. 29. Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, CAMS&PUMC, Beijing, China.
Abstract
OBJECTIVE: The impact of participating in breast cancer screening programmes on health-related quality of life (HRQoL)is poorly understood. METHODS: Based on a national breast cancer screening programme in China, a multicentre cross-sectional survey was conducted covering 12 provinces from September 2013 to December 2014. HRQoL of participants in the screening population and general population was evaluated by the three-levelEuroQol-five-Dimensions (EQ-5D-3L) instrument, and utility scores were generated through the Chinese value set. Univariate and multivariate regression analyses were performed to explore determinants of utility scores and anxiety/depression problems. RESULTS: For screening group and general population (n = 4756, mean age = 51.6 year old), the corresponding utility scores were 0.937 (95% CI, 0.933-0.941) and 0.953 (0.949-0.957) (P < .001). Pain/discomfort and anxiety/depression were the most common reported in both groups (51.4% and 34.3%, P < .001). Utility scores at prescreening, in-screening, and postscreening interview timings were 0.928 (0.921-0.935), 0.958 (0.948-0.969), and 0.938 (0.933-0.943), respectively (P < .001); the corresponding proportions of anxiety/depression reporting were 25.9%, 16.3%, and 21.1%, respectively (P = .004). Interview timing, geographical region, and insurance status were associated with HRQoL and anxiety/depression in women at high-risk of breast cancer. CONCLUSIONS: Utility scores of screening participants were significantly lower than that of general population in China, but the difference may be clinically insignificant. Further cohort studies using HRQoL measurements are needed.
OBJECTIVE: The impact of participating in breast cancer screening programmes on health-related quality of life (HRQoL)is poorly understood. METHODS: Based on a national breast cancer screening programme in China, a multicentre cross-sectional survey was conducted covering 12 provinces from September 2013 to December 2014. HRQoL of participants in the screening population and general population was evaluated by the three-levelEuroQol-five-Dimensions (EQ-5D-3L) instrument, and utility scores were generated through the Chinese value set. Univariate and multivariate regression analyses were performed to explore determinants of utility scores and anxiety/depression problems. RESULTS: For screening group and general population (n = 4756, mean age = 51.6 year old), the corresponding utility scores were 0.937 (95% CI, 0.933-0.941) and 0.953 (0.949-0.957) (P < .001). Pain/discomfort and anxiety/depression were the most common reported in both groups (51.4% and 34.3%, P < .001). Utility scores at prescreening, in-screening, and postscreening interview timings were 0.928 (0.921-0.935), 0.958 (0.948-0.969), and 0.938 (0.933-0.943), respectively (P < .001); the corresponding proportions of anxiety/depression reporting were 25.9%, 16.3%, and 21.1%, respectively (P = .004). Interview timing, geographical region, and insurance status were associated with HRQoL and anxiety/depression in women at high-risk of breast cancer. CONCLUSIONS: Utility scores of screening participants were significantly lower than that of general population in China, but the difference may be clinically insignificant. Further cohort studies using HRQoL measurements are needed.
Authors: Juan Zhu; Xin-Xin Yan; Cheng-Cheng Liu; Hong Wang; Le Wang; Su-Mei Cao; Xian-Zhen Liao; Yun-Feng Xi; Yong Ji; Lin Lei; Hai-Fan Xiao; Hai-Jing Guan; Wen-Qiang Wei; Min Dai; Wanqing Chen; Ju-Fang Shi Journal: Qual Life Res Date: 2020-09-15 Impact factor: 4.147
Authors: Alexandra Roux; Rachel Cholerton; Jonathan Sicsic; Nora Moumjid; David P French; Paolo Giorgi Rossi; Corinne Balleyguier; Michal Guindy; Fiona J Gilbert; Jean-Benoit Burrion; Xavier Castells; David Ritchie; Debbie Keatley; Camille Baron; Suzette Delaloge; Sandrine de Montgolfier Journal: BMC Cancer Date: 2022-05-06 Impact factor: 4.638
Authors: Xin-Xin Yan; Juan Zhu; Yan-Jie Li; Meng-Di Cao; Xin Wang; Hong Wang; Cheng-Cheng Liu; Jing Wang; Yang Li; Ju-Fang Shi Journal: Popul Health Metr Date: 2022-10-07